Skip to content
Triangle logo TriangleGet started
← All settings

DISEASE & TREATMENT SETTING

Gastrointestinal Neuroendocrine Tumors

Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.

Exact scope

Gastrointestinal Neuroendocrine Tumors

Source population
Not part of this definition
Disease extent
Not part of this definition
Treatment line
Not part of this definition
Stage
Not part of this definition
Resectability
Not part of this definition
Biomarkers, prior therapy and derivation
molecular
    prior therapy
      derivation status
      clinically-proposed
      derivation note
      Derived from NCI topic(s): Gastrointestinal Neuroendocrine Tumors. Strongest NCIt resolution: candidate. Entity-level scope; stage, biomarker and treatment line are not yet part of this definition.
      source wording
      Source null
      2 more-specific settings
      metastatic Gastrointestinal Neuroendocrine Tumors →recurrent Gastrointestinal Neuroendocrine Tumors →

      Study evidence for this setting

      7 linked studies · Applicability is a draft source assessment, not a determination of your eligibility.

      NCT00903396 · Registry condition search · Scope: narrower

      Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer

      5 outcome links · 4 safety-group records · 0 quality-of-life measures

      →

      NCT01010126 · Registry condition search · Scope: narrower

      Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer

      6 outcome links · 6 safety-group records · 0 quality-of-life measures

      →

      NCT01869725 · Registry condition search · Scope: narrower

      Comparative Study of Sensitivity of Ga-DOTATOC PET vs Octreoscan SPECT + CT

      3 outcome links · 1 safety-group records · 0 quality-of-life measures

      →

      NCT03375320 · Source cited / selected · Scope: narrower

      Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

      4 outcome links · 4 safety-group records · 2 quality-of-life measures

      →

      NCT04505553 · Registry condition search · Scope: narrower

      Oral Cryotherapy Plus Acupressure and Acupuncture Versus Oral Cryotherapy for Decreasing Chemotherapy-Induced Peripheral Neuropathy From Oxaliplatin-Based Chemotherapy in Patients

      6 outcome links · 2 safety-group records · 2 quality-of-life measures

      →

      NCT04579679 · Registry condition search · Scope: narrower

      Open-Label Surufatinib in European Patients With NET

      6 outcome links · 4 safety-group records · 0 quality-of-life measures

      →

      NCT04711135 · Source cited / selected · Scope: narrower

      Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs

      6 outcome links · 3 safety-group records · 0 quality-of-life measures

      →
      Source relationships and population-mapping limitations
      bindings
      1. release id
        clinical-indications-draft-1
        disease state id
        ds-gastrointestinal-neuroendocrine-tumors
        binding id
        ncit-C95404
        source collection
        ncit-concept
        source key
        C95404
        source excerpt
        Source null
        match status
        candidate
        match note
        Resolution status: candidate.
        recorded at
        2026-09-10T00:00:00Z
      mappings

        Download this complete draft source relationship record →

        Preserved source evidence · Not medical advice